跳至主要内容
临床试验/NCT07327424
NCT07327424进行中(未招募)不适用

Feasibility of Suprapubic Transvesical Endoscopic Prostatectomy

Beni-Suef University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年7月15日最近更新:
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
80
试验地点
1
主要终点
International Prostate Symptom Score

研究概览

简要总结

In patients with penile prosthesis, any transurethral procedure could place the implant at risk. The use of long or extra-long resectoscope can be of some assistance; however, these are not available in many institutions. So suprapubic transvesical endoscopic prostatectomy is newly developed to bypass the anterior urethra. Thus, the aim of this study is to determine safety and efficacy of Suprapubic Transvesical endoscopic prostatectomy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male patients with moderate to severe lower urinary tract symptoms ( IPSS score ≥ 8 ) indicated for surgical intervention with prostate size less than 120 cc.

排除标准

  • History of previous pelvic surgery, urothelial cancer, kidney transplantation, uncontrolled coagulopathy, and significant central fat accumulation that could potentially increase the risk during transvesical access(body mass index not exceeding 27 kg/m2)

研究组 & 干预措施

Suprapubic Transvesical endoscopic prostatectomy

Experimental

干预措施: Suprapubic transvesical endoscopic prostatectomy (Other)

结局指标

主要结局

International Prostate Symptom Score

时间窗: 6 months

次要结局

  • Q max(6 months)
  • PVR (post-void residual volume)(6 MONTHS)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed M Abdelbary, MD

Ahmed Abdelbary

Beni-Suef University

研究点 (1)

Loading locations...

相似试验

Feasibility of Suprapubic Transvesical Endoscopic... | 临床试验